Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15385434
Masri B, et al. (2004) Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 18, 1909-11 15385434
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
wortmannin apelin inhibit treatment-induced increase
SH-6 apelin inhibit treatment-induced increase
rapamycin apelin no effect upon treatment-induced increase
PTX apelin inhibit treatment-induced increase
GF109203X apelin inhibit treatment-induced increase
PKC_inhibitor_myristoylated apelin inhibit treatment-induced increase

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
wortmannin apelin inhibit treatment-induced increase
SH-6 apelin inhibit treatment-induced increase
rapamycin apelin no effect upon treatment-induced increase
PTX apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
herbimycin_A apelin inhibit treatment-induced increase
GF109203X apelin inhibit treatment-induced increase
PKC_inhibitor_myristoylated apelin inhibit treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
PP1 apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
phorbol_ester apelin augment treatment-induced increase
phorbol_ester increase pretreatment with phorbol ester inhibits increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
PP1 apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
phorbol_ester apelin augment treatment-induced increase
phorbol_ester increase pretreatment with phorbol ester inhibits increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
PP1 apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
phorbol_ester apelin augment treatment-induced increase
phorbol_ester increase pretreatment with phorbol ester inhibits increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
PP1 apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
phorbol_ester apelin augment treatment-induced increase
phorbol_ester increase pretreatment with phorbol ester inhibits increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
wortmannin apelin inhibit treatment-induced increase
SH-6 apelin inhibit treatment-induced increase
rapamycin apelin inhibit treatment-induced increase
PTX apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
herbimycin_A apelin inhibit treatment-induced increase
GF109203X apelin inhibit treatment-induced increase
PKC_inhibitor_myristoylated apelin inhibit treatment-induced increase
PD98059 apelin inhibit treatment-induced increase
phorbol_ester increase pretreatment with phorbol ester inhibits increase

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
wortmannin apelin no effect upon treatment-induced increase
SH-6 apelin inhibit treatment-induced increase
rapamycin apelin no effect upon treatment-induced increase
PTX apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
herbimycin_A apelin inhibit treatment-induced increase
GF109203X apelin inhibit treatment-induced increase
PKC_inhibitor_myristoylated apelin inhibit treatment-induced increase
phorbol_ester increase pretreatment with phorbol ester inhibits increase

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CHO (fibroblast), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  hamster, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
apelin increase
wortmannin apelin no effect upon treatment-induced increase
SH-6 apelin inhibit treatment-induced increase
rapamycin apelin no effect upon treatment-induced increase
PTX apelin inhibit treatment-induced increase
PP2 apelin inhibit treatment-induced increase
herbimycin_A apelin inhibit treatment-induced increase
GF109203X apelin inhibit treatment-induced increase
PKC_inhibitor_myristoylated apelin inhibit treatment-induced increase
phorbol_ester increase pretreatment with phorbol ester inhibits increase